Do analysts recommend RNTX or PLUR?

Rein Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 611.24%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is RNTX or PLUR more profitable?

Rein Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A N/A -63.69% Pluri -2,162.08% N/A -106.59%

Does the media refer more to RNTX or PLUR?

In the previous week, Rein Therapeutics had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Rein Therapeutics and 1 mentions for Pluri. Rein Therapeutics' average media sentiment score of 0.92 beat Pluri's score of 0.45 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pluri 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate XBIT or PLUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, XBIT or PLUR?

Pluri has higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.48 N/A Pluri $1.34M 11.40 -$22.58M -$4.53 N/A

Is XBIT or PLUR more profitable?

XBiotech has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat XBiotech's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -31.62% -30.29% Pluri -2,162.08% N/A -106.59%

Does the media favor XBIT or PLUR?

In the previous week, XBiotech had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for XBiotech and 1 mentions for Pluri. XBiotech's average media sentiment score of 0.58 beat Pluri's score of 0.45 indicating that XBiotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pluri 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PMVP or PLUR?

PMV Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 222.58%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe PMV Pharmaceuticals is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to PMVP or PLUR?

In the previous week, PMV Pharmaceuticals had 6 more articles in the media than Pluri. MarketBeat recorded 7 mentions for PMV Pharmaceuticals and 1 mentions for Pluri. Pluri's average media sentiment score of 0.45 beat PMV Pharmaceuticals' score of -0.21 indicating that Pluri is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PMV Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Pluri 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PLUR or EXOZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, PLUR or EXOZ?

eXoZymes has lower revenue, but higher earnings than Pluri. eXoZymes is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.34M 11.40 -$22.58M -$4.53 N/A eXoZymes $70K 901.49 -$9.16M -$1.19 N/A

Is PLUR or EXOZ more profitable?

eXoZymes has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% eXoZymes N/A -292.15% -158.66%

Do analysts prefer INMB or PLUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, INMB or PLUR?

Pluri has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INmune Bio $50K 1,259.85 -$45.93M -$0.67 N/A Pluri $1.34M 11.40 -$22.58M -$4.53 N/A

Is INMB or PLUR more profitable?

INmune Bio has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Pluri -2,162.08% N/A -106.59%

Does the media favor INMB or PLUR?

In the previous week, INmune Bio had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for INmune Bio and 1 mentions for Pluri. INmune Bio's average media sentiment score of 1.09 beat Pluri's score of 0.45 indicating that INmune Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pluri 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pluri (PLUR) Competitors

$1.37 -0.05 (-3.52%)

As of 04:00 PM Eastern

Compare

PLUR vs. RNTX, XBIT, PMVP, EXOZ, and INMB

Should you buy Pluri stock or one of its competitors? Pluri's main competitors and comparable companies include Rein Therapeutics (RNTX), XBiotech (XBIT), PMV Pharmaceuticals (PMVP), eXoZymes (EXOZ), and INmune Bio (INMB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pluri compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Rein Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 611.24%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pluri has higher revenue and earnings than Rein Therapeutics. Rein Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A
Pluri	$1.34M	11.40	-$22.58M	-$4.53	N/A

Rein Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Pluri has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Rein Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-63.69%
Pluri	-2,162.08%	N/A	-106.59%

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by company insiders. Comparatively, 43.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Rein Therapeutics had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Rein Therapeutics and 1 mentions for Pluri. Rein Therapeutics' average media sentiment score of 0.92 beat Pluri's score of 0.45 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pluri	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rein Therapeutics beats Pluri on 10 of the 14 factors compared between the two stocks.

How does Pluri compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pluri has higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Pluri	$1.34M	11.40	-$22.58M	-$4.53	N/A

XBiotech has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Pluri has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

XBiotech has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
Pluri	-2,162.08%	N/A	-106.59%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, XBiotech had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for XBiotech and 1 mentions for Pluri. XBiotech's average media sentiment score of 0.58 beat Pluri's score of 0.45 indicating that XBiotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pluri	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

XBiotech beats Pluri on 7 of the 12 factors compared between the two stocks.

How does Pluri compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Pluri has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A
Pluri	$1.34M	11.40	-$22.58M	-$4.53	N/A

PMV Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
Pluri	-2,162.08%	N/A	-106.59%

In the previous week, PMV Pharmaceuticals had 6 more articles in the media than Pluri. MarketBeat recorded 7 mentions for PMV Pharmaceuticals and 1 mentions for Pluri. Pluri's average media sentiment score of 0.45 beat PMV Pharmaceuticals' score of -0.21 indicating that Pluri is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PMV Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Pluri	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PMV Pharmaceuticals has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Pluri has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 10.2% of PMV Pharmaceuticals shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PMV Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 222.58%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe PMV Pharmaceuticals is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PMV Pharmaceuticals beats Pluri on 10 of the 16 factors compared between the two stocks.

How does Pluri compare to eXoZymes?

Pluri (NASDAQ:PLUR) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

16.6% of Pluri shares are held by institutional investors. 43.2% of Pluri shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

eXoZymes has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
eXoZymes	N/A	-292.15%	-158.66%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, eXoZymes had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for eXoZymes and 1 mentions for Pluri. eXoZymes' average media sentiment score of 1.00 beat Pluri's score of 0.45 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Overall Sentiment
Pluri	Neutral
eXoZymes	Positive

Pluri has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, suggesting that its stock price is 214% more volatile than the broader market.

eXoZymes has lower revenue, but higher earnings than Pluri. eXoZymes is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	11.40	-$22.58M	-$4.53	N/A
eXoZymes	$70K	901.49	-$9.16M	-$1.19	N/A

Summary

eXoZymes beats Pluri on 8 of the 13 factors compared between the two stocks.

How does Pluri compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

INmune Bio has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Pluri has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Pluri has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,259.85	-$45.93M	-$0.67	N/A
Pluri	$1.34M	11.40	-$22.58M	-$4.53	N/A

INmune Bio has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Pluri	-2,162.08%	N/A	-106.59%

In the previous week, INmune Bio had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for INmune Bio and 1 mentions for Pluri. INmune Bio's average media sentiment score of 1.09 beat Pluri's score of 0.45 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pluri	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 21.4% of INmune Bio shares are held by insiders. Comparatively, 43.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

INmune Bio beats Pluri on 9 of the 15 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLUR vs. The Competition

Export

Metric	Pluri	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.83M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.30	12.66	273.28	25.38
Price / Sales	11.40	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	-12.45	16.29	12.89	6.14
Net Income	-$22.58M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-10.46%	-1.37%	-0.33%	-1.47%
1 Month Performance	-11.33%	11.07%	6.51%	2.47%
1 Year Performance	-73.40%	53.71%	25.19%	15.84%

Pluri Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLUR Pluri	0.8449 of 5 stars	$1.37 -3.5%	N/A	-72.9%	$15.83M	$1.34M	N/A	150
RNTX Rein Therapeutics	3.0879 of 5 stars	$0.82 +1.9%	$6.00 +636.2%	-42.6%	$70.31M	N/A	N/A	9	News Coverage
XBIT XBiotech	0.4326 of 5 stars	$2.31 +0.2%	N/A	-27.5%	$70.28M	N/A	N/A	100	News Coverage Analyst Downgrade
PMVP PMV Pharmaceuticals	3.2421 of 5 stars	$1.31 +0.7%	$4.00 +204.4%	-15.4%	$70.25M	N/A	N/A	50
EXOZ eXoZymes	1.4968 of 5 stars	$7.52 -0.2%	N/A	-29.9%	$69.74M	$70K	N/A	29	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLUR) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pluri (PLUR) Competitors

PLUR vs. RNTX, XBIT, PMVP, EXOZ, and INMB

How does Pluri compare to Rein Therapeutics?

Summary

How does Pluri compare to XBiotech?

Summary

How does Pluri compare to PMV Pharmaceuticals?

Summary

How does Pluri compare to eXoZymes?

Summary

How does Pluri compare to INmune Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR vs. The Competition

Pluri Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pluri (PLUR) Competitors

PLUR vs. RNTX, XBIT, PMVP, EXOZ, and INMB

How does Pluri compare to Rein Therapeutics?

Do analysts recommend RNTX or PLUR?

Which has higher valuation and earnings, RNTX or PLUR?

Which has more volatility & risk, RNTX or PLUR?

Is RNTX or PLUR more profitable?

Do institutionals & insiders have more ownership in RNTX or PLUR?

Does the media refer more to RNTX or PLUR?

Summary

How does Pluri compare to XBiotech?

Do institutionals and insiders believe in XBIT or PLUR?

Which has higher earnings and valuation, XBIT or PLUR?

Which has more risk & volatility, XBIT or PLUR?

Is XBIT or PLUR more profitable?

Do analysts rate XBIT or PLUR?

Does the media favor XBIT or PLUR?

Summary

How does Pluri compare to PMV Pharmaceuticals?

Which has preferable valuation and earnings, PMVP or PLUR?

Is PMVP or PLUR more profitable?

Does the media refer more to PMVP or PLUR?

Which has more volatility & risk, PMVP or PLUR?

Do insiders and institutionals believe in PMVP or PLUR?

Do analysts rate PMVP or PLUR?

Summary

How does Pluri compare to eXoZymes?

Do insiders & institutionals have more ownership in PLUR or EXOZ?

Is PLUR or EXOZ more profitable?

Do analysts recommend PLUR or EXOZ?

Does the media prefer PLUR or EXOZ?

Which has more volatility & risk, PLUR or EXOZ?

Which has better earnings and valuation, PLUR or EXOZ?

Summary

How does Pluri compare to INmune Bio?

Which has more risk and volatility, INMB or PLUR?

Which has stronger earnings & valuation, INMB or PLUR?

Is INMB or PLUR more profitable?

Does the media favor INMB or PLUR?

Do institutionals and insiders hold more shares of INMB or PLUR?

Do analysts prefer INMB or PLUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR vs. The Competition

Pluri Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools